Vimarsana
Biggest News Aggregation in the World

Page 19 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC - Vimarsana News

FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC

The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP - Vimarsana News

Outlook Therapeutics® Adds Global Commercial Expertise with Appointment of Jedd Comiskey as Senior VP

ISELIN, N.J., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA approval for the first ophthalmic formulation of bevacizumab for the treatment of retinal diseases, today announced the appointment of Jedd Comiskey as Senior VP – Head of Europe. Mr. Comiskey has a successful track record in the planning, organization and execution of product launches. Over the course of his career, he has demonstrated innovative, solutio

Source: yahoo.com
PD-L1 IHC 22C3 pharmDx Gets Green Light From FDA for Determining Pembrolizumab Eligibility in Gastric/GEJ Adenocarcinoma - Vimarsana News

PD-L1 IHC 22C3 pharmDx Gets Green Light From FDA for Determining Pembrolizumab Eligibility in Gastric/GEJ Adenocarcinoma

The FDA has approved the PD-L1 IHC 22C3 pharmDx diagnostic tool to aid clinicians in identifying patients with gastric or gastroesophageal junction adenocarcinoma who may be eligible for treatment with the PD-1 inhibitor pembrolizumab.

US Drug Regulator Approves Valneva's Single-Shot Chikungunya Vaccine - Vimarsana News

US Drug Regulator Approves Valneva's Single-Shot Chikungunya Vaccine

FDA approves Valneva's Ixchiq vaccine for ages 18+, the first single-shot for chikungunya. Learn about symptoms, availability, and trial results

Source: news18.com
FDA: New Obesity Drug Approved, Creator Claims It Helps Lose 20% Weight - Vimarsana News

FDA: New Obesity Drug Approved, Creator Claims It Helps Lose 20% Weight

The FDA has approved a new weight loss drug, with its trials claiming it can help lose your extra pounds.